Increased glia‐specific transgene expression with glial fibrillary acidic protein promoters containing multiple enhancer elements
- 22 February 2006
- journal article
- research article
- Published by Wiley in Journal of Neuroscience Research
- Vol. 83 (5) , 744-753
- https://doi.org/10.1002/jnr.20776
Abstract
The ability to direct transgene expression to astrocytes has become increasingly important as the roles for these cells continue to expand. Promoters consisting of the 5′-flanking region of the human or mouse glial fibrillary acidic protein (GFAP) gene have generally proved satisfactory. However, a more powerful promoter would be advantageous for several applications, such as expression of dominant negative RNAs or proteins, or for gene therapy. We investigated the possibility of increasing the transcriptional activity of the human GFAP promoter by inserting into it one or three additional copies of putative GFAP enhancer regions. The promoters enhanced with three additional copies gave 75-fold higher LacZ expression levels upon plasmid transfection into GFAP-expressing U251 cells than the parental gfa2 promoter. Surprisingly, in a transgenic mouse model, the enhanced promoters resulted in no or only very low expression of marker genes, probably caused by toxicity. When various cell lines were infected with replication-deficient adenoviral vectors, the enhanced promoters gave LacZ expression levels that were approximately 10-fold higher than those with the parental gfa2 promoter, while retaining specificity for GFAP-expressing cells. Injection of the adenoviral vectors carrying the enhanced promoters into nude mouse brain showed that LacZ expression was limited to GFAP-positive cells. We conclude that gfa2 enhanced promoters are useful for production of short-term, glia-specific, high expression levels of genes in an adenoviral context. Adenoviral vectors containing these enhanced promoters may be useful in glioma gene therapy.Keywords
This publication has 31 references indexed in Scilit:
- Evaluation of tissue‐specific promoters in carcinomas of the cervix uteriThe Journal of Gene Medicine, 2004
- A Novel TARP-Promoter-Based Adenovirus against Hormone-Dependent and Hormone-Refractory Prostate CancerMolecular Therapy, 2004
- Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's diseaseGene Therapy, 2004
- The glial identity of neural stem cellsNature Neuroscience, 2003
- Superior Tissue-Specific Expression from Tyrosinase and Prostate-Specific Antigen Promoters/Enhancers in Helper-Dependent Compared with First-Generation Adenoviral VectorsHuman Gene Therapy, 2002
- Specific tumor-cell killing with adenovirus vectors containing the apoptin geneGene Therapy, 1999
- β-Galactosidase Gene Transfer to Human Malignant Glioma In Vivo Using Replication-Deficient Retroviruses and AdenovirusesHuman Gene Therapy, 1998
- Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expressionGene Therapy, 1997
- Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral VectorsHuman Gene Therapy, 1996
- GFAP and AstrogliosisBrain Pathology, 1994